Avid Radiopharmaceuticals
Kelly Conway has a diverse work experience in the field of biology and pharmacology. Kelly began their career at Harvard Medical School as a Postdoctoral Fellow in Neurology from 1999 to 2000. Kelly then joined Johnson & Johnson Pharmaceutical Research and Development as a Senior Scientist from 2000 to 2007. In 2008, they started working at Avid Radiopharmaceuticals, where they held various roles such as Senior Pharmacologist from 2008 to 2014, Research Fellow in Pharmacology from 2014 to 2015, Associate Director of In Vitro Biology from 2015 to present, and currently serves as the Director of Biology since May 2018.
Kelly Conway attended Princeton University from 1982 to 1986, where they obtained a Bachelor of Arts degree in Chemistry. Kelly then pursued further education at the Massachusetts Institute of Technology from 1994 to 1999, earning a Ph.D. in Chemistry.
This person is not in any teams
Avid Radiopharmaceuticals
1 followers
At Avid, a wholly owned subsidiary of Eli Lilly and Company, our mission is to develop new molecular imaging agents capable of changing the medical management of significant chronic human diseases. We have assembled an outstanding management team with extensive imaging and CNS development experience to help make pre-symptomatic disease detection a reality. Avid's pipeline of imaging compounds has the potential to dramatically alter the clinical course of challenging conditions such as Alzheimer's disease, Dementia with Lewy Bodies, Parkinson's disease and Diabetes Mellitus. This may be possible because our molecular imaging compounds may be able to detect the first stages of pathological change; allowing early treatment and management of people at risk - perhaps before before symptoms of disease can develop.